chaleur is being built as a grant-funded public good, not a commercial product.
The intended path to people is institutional distribution through a clinical partner, councils, or primary health networks, rather than an app-store launch. To take the next step, two things are needed.
A research-active clinical partner
Someone to help develop and review the health guidance — the clinical content is open to a partner's input, not finished and waiting for a signature — co-design a pilot, and help anchor the project's clinical credibility.
Grant funding for a pilot
Support for a council or state-level pilot, including the equity framing and the question of where the running cost lives after the grant.
How chaleur's alerts are grounded
Independent of the question of overall benefit, the content of every alert is built to a standard a clinical reviewer can check. The severity thresholds that decide when each hazard becomes alert-worthy, and the advice shown to a carer, are drawn from official Australian public-health sources, including NSW Health, the Bureau of Meteorology's heatwave service, ARPANSA for ultraviolet radiation, state environment agencies for air quality, and the Victorian thunderstorm asthma risk forecast. chaleur does not author medical advice of its own; it presents attributed official guidance. Where the official sources do not map cleanly onto the app, which happens, for example, where no published threshold converts a pollen count and a storm signal into a single risk level, the gap is recorded and flagged as a decision for a clinical partner rather than filled by guesswork. All of this content is provisional and carries that status openly until a qualified clinician has reviewed it, which is one of the concrete tasks a clinical partnership would take on. Nothing reaches the public on the strength of that assembly alone: each item is held as provisional until a named clinician reviews and signs it, and the data the app holds about a vulnerable person is treated as sensitive by design. For a clinical partner this means the collaboration begins from a controlled, reviewable position rather than an already-shipped product.
Opportunities for research
chaleur is also a way to study questions the field has not yet answered, and a clinical partner inclined toward research would find several that are both open and fundable. The Evidence page sets out three in detail: whether a timely prompt to check in on an isolated person measurably reduces harm, a protective effect so far established only in observational data; whether a warning that names the threat to a specific person changes behaviour more than a general broadcast, which the literature suggests but has not demonstrated on health outcomes; and whether addressing the warning to a carer rather than the at-risk person reaches the people a general warning misses, or whether it inherits the same optimism people tend to hold about their own risk. Each is a question a pilot built on chaleur could be designed to answer, with defined behavioural and check-in endpoints, and the app is built to support that kind of study rather than to foreclose it. A partner who wanted to publish from the pilot, or to shape its endpoints around their own research interest, would be working with the grain of the project.
Who you would be working with
A partnership would begin as a collaboration with chaleur's founder, Natasha Roumanoff, who built the working prototype and whose professional background is in privacy, information security and compliance in regulated environments. A fuller account of that background, including the delivery record behind it, is under About Natasha.